within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX67_Tagraxofusp;
model Tagraxofusp 
   extends Pharmacolibrary.Drugs.ATC.L.L01XX67;

  annotation(Documentation(
    info ="<html><body><p>Tagraxofusp (SL-401) is a fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Tagraxofusp is approved for adult and pediatric patients 2 years and older with BPDCN.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with BPDCN, after intravenous infusion. Values primarily reflect population PK analyses from clinical studies.</p><h4>References</h4><ol><li><p>Syed, YY (2019). Tagraxofusp: First Global Approval. <i>Drugs</i> 79(5) 579â€“583. DOI:<a href=&quot;https://doi.org/10.1007/s40265-019-01087-z&quot;>10.1007/s40265-019-01087-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30859413/&quot;>https://pubmed.ncbi.nlm.nih.gov/30859413</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Tagraxofusp;
